Development of a therapeutic monoclonal antibody that targets secreted fatty acid–binding protein aP2 to treat type 2 diabetes-Reference-Cited by-同舟云学术

Development of a therapeutic monoclonal antibody that targets secreted fatty acid–binding protein aP2 to treat type 2 diabetes

Published:2015-12-23 Issue:319 Volume:7 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Burak M. Furkan¹,Inouye Karen E.¹,White Ariel¹,Lee Alexandra¹,Tuncman Gurol¹,Calay Ediz S.¹,Sekiya Motohiro¹,Tirosh Amir¹,Eguchi Kosei¹,Birrane Gabriel²,Lightwood Daniel³,Howells Louise³,Odede Geofrey³,Hailu Hanna³,West Shauna³,Garlish Rachel³,Neale Helen³,Doyle Carl³,Moore Adrian³,Hotamisligil Gökhan S.¹⁴

Affiliation:

1. Department of Genetics and Complex Diseases and Sabri Ülker Center, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.

2. Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.

3. UCB (Union Chimique Belge), 208 Bath Road, Slough, Berkshire SL1 3WE, UK.

4. Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.

Abstract

A monoclonal antibody to fatty acid–binding protein aP2 has antidiabetic effects on glucose output and utilization.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference60 articles.